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Since astemizole in an oral dose of 50 mg/kg/day was recently reported to exert anti-cancer effect in
mice, we evaluated its proarrhythmic potential using the atrioventricular block dogs in order to clarify its
cardiac safety proﬁle. An oral dose of 3 mg/kg prolonged the QT interval without affecting the QTc
(n ¼ 4), whereas that of 30 mg/kg increased the short-term variability of repolarization and induced
premature ventricular contractions in each animal, resulting in the onset of torsade de pointes in 1
animal (n ¼ 4). Thus, proarrhythmic dose of astemizole would be lower than anti-cancer one, limiting its
re-proﬁling as an anti-cancer drug.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).While astemizole was developed as a second-generation hista-
mine type 1 antagonist, it has been shown to block human ether-
a-go-go-related gene (hERG) Kþ channel (1), and to induce the QT-
interval prolongation and torsade de pointes in patients, which
led the drug to withdraw from the commercial market in 1999 (1).
Recently, ether a-go-go-1 (Eag1) as well as hERG Kþ channels have
been reported to be highly expressed in various cancer cells, and
blockade of either channel was shown to inhibit proliferation of the
cancer (2). Since astemizole was found to inhibit Eag1 in addition to
hERG Kþ channels, it has gained enormous interest again as a new
anti-cancer drug, (1,3). By now, astemizole has been shown to
suppress cervical cancer cell proliferation by increasing apoptosis
at concentrations of 2 and 5 mM in vitro (3); moreover, to inhibit
human breast cancer cell growth in an oral dose of 50 mg/kg/day
for 3 weeks in mice (4). Since experimental evidence showing a
direct causal link between astemizole administration and onset of
torsade de pointes remains still limited (5), we precisely evaluated
the extent of its proarrhythmic potential in order to begin to re-
proﬁle astemizole as an anti-cancer drug. For this purpose, we
adopted the chronic atrioventricular block caninemodel, which has
been widely used for quantifying the torsadogenic potential of
many drugs (6).1; fax: þ81 3 5493 5413.
p (A. Sugiyama).
rmacological Society.
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d/4.0/).All experiments were approved by the Animal Research Com-
mittee for Animal Experimentation of Toho University (No. 15-55-
152) and performed in accordance with the Guidelines for the Care
and Use of Laboratory Animals of Toho University. Atrioventricular
block model was prepared using 4 beagle dogs of either sex
weighing approximately 10 kg. The animals were obtained through
Kitayama Labes Co., Ltd. (Nagano). The catheter ablation was used
for producing complete atrioventricular block with an onset of
stable idioventricular escaped rhythm as previously described (6).
Experiments were performed 4 weeks after the induction of
complete atrioventricular block (6). A Holter recording and analysis
system (QR2100 and HS1000, Fukuda M-E Kogyo Co., Ltd., Tokyo)
was used to record and analyze electrocardiogram over 24 h. The
effects of astemizole on the idioventricular rate, QT interval and
corrected QT calculated with the Fridericia's formula (QTcF):
QTcF ¼ QT/(RR/1000)1/3 in addition to its proarrhythmic events
were assessed without anesthesia. The idioventricular rate, QT in-
terval and QTcF were expressed as the mean of 10 consecutive
complexes. In this study, torsade de pointes was deﬁned as a
polymorphic ventricular tachycardia associated with QT-interval
prolongation, consisting of 5 beats or more twisting QRS com-
plexes around the baseline (7). On the ﬁrst day, 2 h after the start of
Holter electrocardiogram recording, 3 mg/kg of astemizole (Sig-
maeAldrich, St. Louis, MO, USA) was orally administered at 10:00
amwith gelatin capsules (J.P No.00, Kobayashi capsule, Hyogo). On
the second day, 30mg/kg of the drugwas orally administered in thenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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0.5e1 h before, and 1, 2, 3, 4, 6, 8, 12 and 21 h after the start of the
administration.
Poincare plots with QTn versus QTnþ1 were prepared for each of
two analysis time points; namely, electrocardiogram of 51
consecutive beats under the stable idioventricular rhythm without
ectopic activity was adopted before and about 2 h after the
administration of 30 mg/kg of astemizole. The mean orthogonal
distance from the diagonal to the points of the Poincare plot was
determined as short-term variability (¼ƩjQTnþ1  QTnj/[50√2]),
whereas themean distance to themean of the parameter parallel to
the diagonal of the Poincare plot was done as long-term variability
(¼ƩjQTnþ1 þ QTn  2QTmeanj/[50√2]) (8).
Data are presented as the mean ± S.E.M. The statistical analysis
was performed by using a software GraphPad Prizm 6 (ver6.03,
GraphPad Software, Inc., La Jolla, CA, USA). The statistical signiﬁ-
cances within a parameter were evaluated by one-way repeated-
measures analysis of variance (ANOVA) followed by a post-hoc test
for mean values comparison. A p-value <0.05 was considered to be
statistically signiﬁcant.
The time courses of the changes in the electrocardiogram vari-
ables and the number of surviving animals after the administra-
tions of astemizole are summarized in Fig. 1 (n ¼ 4 for each dose).
The pre-drug control values (C) of the idioventricular rate, QT in-
terval and QTcFwere 31± 2 beats/min, 319± 18ms and 256± 13 for
the low dose of 3 mg/kg, and those were 31 ± 1 beats/min,
331 ± 17 ms and 270 ± 16 for the high dose of 30 mg/kg,0
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Fig. 1. The time courses of the changes in the idioventricular rate (top), QT interval (midd
administration of astemizole of 3 (left) and 30 (right) mg/kg (n ¼ 4 for each dose). Larger v
after the high dose administration would have made the statistical power smaller to dete
represent signiﬁcant changes from the respective pre-drug control values (C) by p-value <0respectively. The low dose prolonged the QT interval for 6e12 h,
whereas no signiﬁcant change was detected in the other variables.
The high dose hardly affected any of these variables.
Typical tracings of the electrocardiogram showing premature
ventricular contractions by the high dose are depicted in Fig. 2A,
whereas its results of onset of premature ventricular contractions
and torsade de pointes, and of mortality are summarized in Fig. 2B.
The low dose did not induce premature ventricular contraction or
torsade de pointes. The high dose frequently induced premature
ventricular contractions in each animal, but it did not change the
focus of idioventricular rhythm during the observation period as
shown in Fig. 2A. Moreover, the high dose induced torsade de
pointes in 1 out of 4 animals at 2.6 h degenerating into the ven-
tricular ﬁbrillation, which resulted in the animal's death (#3). Two
animals (#2 and #4) were found to be dead 1 and 2 days after the
cessation of the Holter electrocardiogram recording, respectively.
Poincare plots for each animal were depicted in Fig. 2C, indi-
cating that short-term variability increased in each animal irre-
spective of the QT-interval changes. The short-term variability of
repolarization increased, whereas no signiﬁcant change was
detected in the long-term variability as summarized in Table 1.
Since the chronic atrioventricular block model was found to
simulate a patient whowas themost sensitive to blockers of rapidly
activating delayed rectiﬁer Kþ current, we have proposed the
following risk stratiﬁcation of proarrhythmia (6). When torsade de
pointes was induced by 1e3 times of the therapeutic dose, the drug
can be considered to have high risk of proarrhythmia. If torsade de0
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le), and QTcF and the number of surviving animals (bottom) before and after the oral
ariability of the QT interval together with decrease of the number of surviving animals
ct the QT-interval prolongation. Data are presented as mean ± S.E.M. Closed symbols
.05.
Fig. 2. Proarrhythmic effects of the oral administration of 30 kg/kg of astemizole. (A) Electrocardiogram before and 2 h 20 min after the dosing. (B) Animals with the onset of
premature ventricular contractions (PVCs), torsade de pointes (TdP) and death due to TdP after the dosing are expressed as gray columns. Hash key (#) represents the animal
number. (C) Poincare plots of the QT interval before and after the dosing. Fifty-one beats were plotted for each of two analysis time points; before (pre: gray) and 1.7e2.3 h after the
dosing (black). Each value of short-term variability (STV) and long-term variability (LTV) of repolarization is depicted in each panel in ms. Note that the animal (#3) which exerted
torsade de pointes showed the longest QT interval and the largest STV.
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induced by its 10e30 times, the drug was judged to have low risk.
In this study, 30 mg/kg, p.o. of astemizole increased the short-term
variability of repolarization irrespective of the extent of the QT-
interval changes (Fig. 2C) and induced premature ventricular con-
tractions in each animal (Fig. 2B), resulting in the onsets of torsade
de pointes in 1 animal during the experimental period and unex-
pected sudden death in 2 animals after the experimental period out
of 4. The latter event might have been induced by highly torsado-
genic astemizole metabolite desmethylastemizole (9,10). In mice,
Cyp2j5 and Cyp2j6 isoforms of Cyp2j family are expressed in the
liver and small intestine (11), making it possible for mice to
metabolize astemizole into desmethylastemizole like in human.
Fifty mg/kg/day, p.o. of astemizole was needed in mice to enhance
anti-neoplastic effects in breast tumors (4), suggesting that the
torsadogenic risk of 30mg/kg, p.o. of astemizole was judged as high
by our risk stratiﬁcation of proarrhythmia, although there may be
some differences in the effective concentrations to produce anti-
neoplastic and arrhythmogenic effects between dogs and mice.
Pharmacokinetic information of astemizole may deserve a
comment in order to better understand currently observed phar-
macodynamic proﬁle. In a previous study using conscious dogs, oral
administration of 3 and 30 mg/kg of astemizole attained the Cmax ofTable 1
Effects of astemizole (30mg/kg, p.o.) on the temporal dispersion of the QT interval in
the chronic atrioventricular block dogs.
Control Post Change
Short-term variability (ms) 6.0 ± 1.5 6.9 ± 1.5** þ0.9 ± 0.1
Long-term variability (ms) 6.3 ± 0.4 7.5 ± 1.4 þ1.2 ± 1.1
Data are represented as mean ± S.E.M. (n ¼ 4). **p-value <0.01, compared with the
respective pre-drug control value (Control). Post: 1.9 ± 0.2 h (1.7e2.3 h) after the
administration of astemizole. The increase of short-term variability predicts the
onset of torsades de pointes.13 ng/mL (28.3 nmol/L) and 178 ng/mL (388 nmol/L), respectively
(10). Meanwhile in a study in healthy 18 young adults, oral
administration of 30 mg/body of astemizole attained the Cmax of
1.9 ng/mL (4.14 nmol/L) (12). The protein-binding ratio of astemi-
zole was reported to be 96.7% (13,14). Although the plasma drug
concentration of astemizole was not measured in this study in or-
der to prevent the inﬂuences of the blood collection procedure on
the onset rate of proarrhythmic events, the Cmax of free plasma
concentrations of each dose of astemizole in this study could be
estimated to be 0.93 and 12.8 nmol/L, respectively, based on the
previous knowledge described above. Since IC50 values of astemi-
zole have been reported to be 28.12 nmol/L for hERG Kþ channel,
0.9878 mmol/L for L-type Ca2þ channel and 1.862 mmol/L for Naþ
channel (15), torsadogenic action in this study would be mainly
explained by hERG Kþ-channel inhibition. Indeed, in a previous
study using in silico adult healthy heart model UT-heart, astemizole
induced torsade de pointes arrhythmias at a free plasma concen-
tration of 58 nmol/L (15). Moreover, astemizole clinically induced
the QT-interval prolongation and torsade de pointes at total plasma
concentrations of 16e250 ng/mL (35e545 nmol/L) (10). Thus, the
pharmacokinetic information further conﬁrms rationale for the use
of the chronic atrioventricular block model, although the model is a
speciﬁc one that can easily produce ventricular arrhythmias.
In conclusion, astemizole in a dose of 30 mg/kg, p.o. caused
torsade de pointes possibly by hERG Kþ-channel inhibition. Proar-
rhythmic dose and concentration of astemizole would be lower
than anti-neoplastic ones, which will limit its re-proﬁling as an
anti-cancer drug, recommending the development of analogs with
more potent Eag1 Kþ-channel inhibitory proﬁle.
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